ITM inks clinical supply agreement with Y-mAbs Therapeutics for nca Lutetium-177
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced the signing of a clinical supply agreement for its medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu/EndolucinBeta) with Y-mAbs Therapeutics, Inc. (Y-mAbs), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
Under the terms of the agreement, ITM will provide its n.c.a. 177Lu for the clinical development of Y-mAbs
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!